Please login to the form below

Not currently logged in
Email:
Password:

trebananib

This page shows the latest trebananib news and features for those working in and with pharma, biotech and healthcare.

Takeda hands back rights to two Amgen drugs

Takeda hands back rights to two Amgen drugs

However, Takeda has decided it is no longer interested in developing pain candidate fulranumab (AMG403) and trebananib (AMG386), which is being tested in cancer. ... In the case of trebananib the picture seems clearer - the compound has already failed

Latest news

  • Amgen's trebananib misses survival target in ovarian cancer Amgen's trebananib misses survival target in ovarian cancer

    Amgen's trebananib misses survival target in ovarian cancer. First phase III trial improved survival rates by just one month. ... he described the overall survival data from TRINOVA-1 as a "binary event" for the trebananib programme.

  • Late-stage ovarian cancer Late-stage ovarian cancer

    Trebananib appears to be closer than nintedanib to approval, given that the primary endpoint (PFS) was achieved in the phase III TRINOVA-1 trial. ... In this trial, 919 patients with recurrent ovarian, primary peritoneal or fallopian tube cancers were

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics